Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 42

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Glioblastoma

Recruiting

Study on the Safety and Effectiveness of a Dendritic Cell Vaccine and Temozolomide for Patients with Glioblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Muscle spasticity

Recruiting

Study comparing Dry Needling and Botulinum Toxin Type A treatments for leg muscle stiffness in stroke patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Universiteit Antwerpen

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Autism spectrum disorder

Recruiting

Studying the Safety of Aripiprazole and Risperidone in Children and Adolescents with Autism Spectrum Disorder

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Aripiprazole
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Epilepsy

Recruiting

Study on Clioquinol for Reducing Seizures in Patients with Drug-Resistant Epilepsy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Clioquinol
  • Sponsor:UZ Leuven

Chronic fatigue syndrome+1

Recruiting

Study on Safinamide and Rasagiline for Treating Fatigue in Parkinson's Disease Patients on Stable Dopaminergic Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rasagiline
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Myasthenia gravis

Recruiting

Study on Nipocalimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Dementia Alzheimer's type

Recruiting

Study on the Effects of Rotigotine and Rivastigmine in Patients with Mild to Moderate Alzheimer's Disease

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Rotigotine
  • Sponsor:Fondazione Santa Lucia

Tuberous sclerosis complex

Recruiting

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Carbamazepine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Encephalitis autoimmune

Recruiting

Study on the Effects and Safety of Inebilizumab for Patients with Anti-NMDA Receptor Encephalitis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Polyneuropathy

Recruiting

Study on Aconite Pain Oil to Prevent and Reduce Symptoms of Chemotherapy-Induced Polyneuropathy in Cancer Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Wala-Heilmittel GmbH

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.